BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS: RECOMMENDATIONS FROM THE INTERNATIONAL WORKING GROUP ON SARCOPENIA


FOR THE INTERNATIONAL WORKING GROUP ON SARCOPENIA

Abstract: Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7-8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.

Key words: Biomarkers, sarcopenia, elderly, skeletal muscle, imaging, screening, follow-up, assessment, aging, consensus paper.

The present article is jointly published in the Journal of Frailty & Aging and in the Journal of Cachexia, Sarcopenia and Muscle

Introduction

One of the most recognized changes in body composition with senescence is the loss of skeletal muscle mass. This loss occurs even among physically active older persons and was originally termed "sarcopenia" for the Greek words "flesh" and "loss" (1). The age-related loss in skeletal muscle mass is associated with substantial social and economic costs and is characterized by impairments in strength, limitations in function, and ultimately physical disability and institutionalization (2-4). In consideration of the increased awareness of this syndrome and the continued rapid development of therapeutic strategies to slow or reverse sarcopenia, the International Working Group on Sarcopenia was convened to address issues related to the successful conduct of clinical trials in this area (5). This task force, consisting of geriatricians and scientists from academia and industry, met again in Toulouse, France in June of 2011, to discuss the current state of the art in the development of biomarkers to be utilized in clinical trials on sarcopenia. The purpose of this meeting was to gain an understanding of the currently available parameters that could be utilized in clinical trials of sarcopenia and to discuss future research needs in this area. Specific topics that were addressed include: review of current consensus definitions of sarcopenia, the importance of muscle performance and quality, biomarkers in other clinical
states and chronic diseases, potential biomarkers for sarcopenia, applications in clinical trials, and recommendations for future studies.

Definition of sarcopenia

Since the advent of the term "sarcopenia" in 1989, there has been a dramatic increase in publications in this area and clinical interest in this condition (6). Originally described as the age-related decrease in skeletal muscle mass (7), until very recently there has been a lack of consensus on the operational definition of sarcopenia without clinically appropriate correlates for this syndrome. In the past two years, a number of academic societies have put forward operational definitions of sarcopenia (8-11). Although each consensus definition has some distinct features, there is general agreement among these groups on the definition of sarcopenia. A summary of consensus sarcopenia definitions is presented in Table 1. The characteristics of sarcopenia highlighted in these reports include: an objective measure of muscle or fat free mass using dual energy x-ray absorptiometry (DXA) or computed tomography (CT), a reliable measure of muscle strength, and/or an objective test of physical functioning. Although the sequence of events and specific recommendations differ somewhat, the general approaches proposed require that patients be identified with measured deficits in physical function for which sarcopenia may be the cause, and subsequently quantification of muscle strength and mass to definitively confirm the diagnosis.

Definition of biomarker

A biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” (12). Hence, biomarkers support the diagnosis, facilitate the tracking of changes over time, and help clinical and therapeutic decision-making processes. Taking this definition into account, the functional, biological, or imaging-related parameters considered in the present document will be hereby generally referred to with the term "biomarker".

There are currently numerous parameters that are potentially able to track the age-related skeletal muscle decline. Depending on the parameter chosen to define sarcopenia, different information might be obtained. Such variability depends on the specific characteristics of each parameter and the mechanisms measured by the parameter. The intrinsic (e.g., accuracy, specificity, sensitivity) and extrinsic (e.g., cost, availability,

<table>
<thead>
<tr>
<th>Group</th>
<th>IANA Sarcopenia Task Force (8)</th>
<th>European Working Group on Sarcopenia in Older People (10)</th>
<th>Special Interest Group: Cachexia-anorexia in Chronic Wasting Diseases (11)</th>
<th>Sarcopenia with Limited Mobility (9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target population</td>
<td>Subjects with clinical declines in physical function, strength, or health status</td>
<td>All persons aged 65 years and older</td>
<td>Older persons</td>
<td>Persons older than 60 years with clinical declines in physical function, strength, or health status. Exclude specific muscle diseases, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, and cachexia</td>
</tr>
<tr>
<td>Screening</td>
<td>Physical function (4-meter gait speed). If gait speed &lt;1.0 m/s, proceed to body composition evaluation</td>
<td>Gait speed. If gait speed ≤0.8 m/s, proceed to body composition evaluation. If gait speed &gt;0.8 m/s, measure hand grip strength; if low muscle strength, proceed to body composition evaluation</td>
<td>Distance walked during a 6-minute walk test (cut-point: 400 meters), or gait speed &lt;1.0 m/s (4 to 6 meter track length)</td>
<td></td>
</tr>
<tr>
<td>Operative definition</td>
<td>Poor functioning plus low ratio between appendicular lean mass (assessed by DXA) and squared height (≤7.23 kg/m² in men, ≤5.67 kg/m² in women)</td>
<td>Low muscle mass in patients with gait speed ≤0.8 m/s, or normal gait speed but low muscle strength</td>
<td>Low muscle mass (≥2 standard deviations below the mean measured in young adults of the same sex and ethnic background) plus low usual gait speed (≤0.8 m/s in the 4-meter walking test). Gait speed test can be replaced by other physical performance measures.</td>
<td>Poor functioning plus low appendicular lean mass (≥2 standard deviations below the mean measured in healthy persons aged 20-30 years old from the same ethnic group)</td>
</tr>
</tbody>
</table>
BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS

Table 2
Possible biomarkers to be used in trials on sarcopenia

<table>
<thead>
<tr>
<th>Muscle function</th>
<th>Inclusion-Exclusion criteria</th>
<th>Baseline evaluation</th>
<th>End-point assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical performance measures</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Muscle strength measures</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Disability</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Muscle mass</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anthropometry</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bioelectrical impedance analysis</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Dual energy X-ray absorptiometry</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Computerized tomography</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Magnetic resonance imaging</td>
<td>++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Echography</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Electrical impedance myography</td>
<td>+</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Mechanisms, biological confounders*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Oxidative damage</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Antioxidants</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Apoptosis</td>
<td>+</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Nutritional parameters (albumin, hemoglobin, urinary creatinine, etc.)</td>
<td>+++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Hormones (dehydroepiandrosterone, testosterone, insulin-like growth factor-1, etc.)</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
</tbody>
</table>

* The importance of all these biomarkers in the evaluation of sarcopenia will largely depend on the study hypotheses, the specific aims, and/or the target population. - : Not recommended for this use; + : may be of use, but severely limited; ++ : suitable for this use; +++ : recommended for this use

The use of biomarkers in a given study must be "fit for purpose". Thus, several different biomarkers may be required to support different aspects of the development of a therapeutic intervention. For example, biomarkers for detection and diagnosis may not be the same as those that ideally track disease progression. Likewise, for new therapeutic agents, a single assay may not suffice as a biomarker reflecting both target engagement and the pharmacodynamic effects of a drug.

**Muscle quantity versus muscle quality**

Although muscle mass can objectively define the presence of sarcopenia, several components of skeletal muscle function are not adequately captured by simply measuring mass or cross-sectional area. It is now clear that there is a certain degree of divergence between changes in muscle mass and alterations in muscle performance. The well-described decline in skeletal muscle mass in older adults is a critical determinant of age-related weakness, which is defined as a reduction in maximal voluntary joint torque or power. Yet, it is now clear that the relationship between force production capability and muscle size in older adults is less robust than it is in young people (13). Indeed, longitudinal studies have demonstrated that the age-related decline in muscle strength far exceeds the observed changes in muscle mass or size, particularly in weight-stable individuals (14, 15). Furthermore, longitudinal studies indicate that maintenance or even gain of muscle mass may not prevent weakness in older adults (15, 16). In addition, a number of age-related changes in force production capability is not readily explained by a reduction in muscle mass, including decreased specific force (force per cross sectional area) (17, 18) and slower rate of isometric force production (expressed relative to peak torque or to body weight) (19, 20). Furthermore, voluntary weight loss leads to reductions in muscle mass/size with no declines in muscle strength (21). It is also noteworthy that pharmacologic interventions that increase muscle mass/size do not necessarily improve voluntary strength. Similarly, physical activity interventions that increase muscle strength do not necessarily augment muscle size (22, 23). Noticeably, gains in muscle strength secondary to increased physical activity generally precede measurable changes in skeletal muscle mass/size.

The progressive muscle atrophy with aging is associated with a loss of overall muscle force and changes in force and power generation of the remaining muscle fibers (24). However, several additional physiological mechanisms that accompany the phenomenon of sarcopenia may directly influence muscle function and force production with advancing
by Baumgartner and colleagues (3) was based on appendicular muscle function through the use of state-of-the-art imaging techniques as well as understanding the sarcopenia phenomenon.

The identification of the “gold standard” for the quantitative evaluation of muscle mass in clinical trials (which is currently lacking) should be based on criteria of accuracy (i.e., the degree of conformity of a measure to a standard or a true value), precision (i.e., the degree of refinement with which an operation is performed or a measurement stated), reproducibility (i.e., the quality of being reproducible under the same operating conditions over a period of time, or by different operators), sensitivity to change (i.e., the degree of being modified by interventions), and accessibility (i.e., its usual availability in research and clinical centers).

DXA currently represents the more accessible technique for body composition assessment. It may accurately provide estimates of lean, fat, and bone tissues in the entire body or in specific regions. Moreover, it is inexpensive and quick to be performed. The radiation exposure associated with DXA is low and highly acceptable (about 1 mrem, a quantity similar to that of a 3-day background). The main limitations of this imaging approach reside in some analytical differences across manufacturers and models, and the risk of biased results due to the low differentiation between water and bone-free lean tissue.

CT accurately measures a direct physical property of the muscle (e.g., cross-sectional area and volume). It also allows the evaluation of muscle density (a parameter related to intramyocellular lipid deposits) as well as subcutaneous and intramuscular adipose tissue deposition. The radiation exposure associated with this technique is higher (i.e., about 15 mrem) than with DXA.

Magnetic resonance imaging (MRI) presents a high agreement with CT and provides similar measures. It does not involve radiation exposure, and also has the additional capacity of multiple slice acquisition, thus rendering 3D volumetric estimates. The lack of radiation exposure makes MRI the method of choice for many studies where ethics committee or national authority approval is more difficult to obtain for CT. The major limitations of this methodology reside in the higher technical complexity and costs, and in the inapplicability to subjects with older models of implanted metal devices (e.g., joint prostheses, pace-makers, etc.). Both CT and MRI may be limited in the ability to accomodate very obese individuals.

Finally, it needs to be emphasized that imaging provides information only about one of the two sarcopenia dimensions. As discussed earlier, changes in muscle function and quantity...
BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS

do not necessarily follow similar trajectories with aging (37). Therefore, interventions able to increase lean mass may not necessarily produce parallel gains in strength and vice versa (38). To overcome this issue and include the two components of sarcopenia in the same variable, it has been proposed to compute an index of skeletal muscle quality derived from the ratio between strength and mass (15, 39, 40).

One of the most recently developed techniques which might find larger application in the near future for the evaluation of sarcopenia is the electrical impedance myography (EIM) (41). This is a noninvasive, painless approach based on the surface application and measurement of a high-frequency, low-intensity electrical current applied to specific muscles. EIM detects changes in the conductivity and permittivity of skeletal muscle caused by alterations in muscle composition and structure. EIM is repeatable and sensitive to skeletal muscle changes in patients with amyotrophic lateral sclerosis (42). Moreover, its changes over time may also have clinical relevance as they are predictive of survival in animal models of amyotrophic lateral sclerosis (43). Finally, it is also noteworthy that the EIM phase shows a consistent inverse relationship with age (44).

An alternative method to measure skeletal muscle size is by ultrasonography. This technique has shown to be a valid (versus MRI-based measurements) and highly reliable way for assessing cross-sectional areas of large individual human muscles (45). It is particularly useful in mobility-impaired subjects who cannot easily be transported to scanners such as CT or MRI machines.

Also remarkable is the development of mass isotopomer distribution analysis based on the evaluation of protein and proteome synthesis rate obtained by heavy water labeling (46, 47). Although this technique can still be considered suitable mainly for research settings, its flexibility and the large amount of information it provides about a wide spectrum of proteins make it extremely promising.

Other techniques are also available to detect sarcopenia, but their limited validation, low accuracy, and difficult large-scale implementation discourage their use. For example, bioelectrical impedance analysis (BIA) is a popular, very simple and low-cost technique, but its results are far from being accurate. The BIA technique is based on the notion that tissues rich in water and electrolytes are less resistant to the electrical passage than adipose tissue. The BIA is therefore based on a single body resistance parameter (not a direct measure of skeletal muscle), and its results can be easily altered by fluid retention and health status in general. For these reasons, a recent consensus paper by the Society of Sarcopenia, Cachexia and Wasting Disorders has discouraged the use of BIA for the assessment of sarcopenia (9).

Definition of critical thresholds

There is still resistance to accept sarcopenia as a clinical condition despite its well-established relationship with major health-related negative events (in particular, mobility and physical disability) (8). This issue might (at least partly) be explained by the current lack of clinically relevant thresholds that distinguish normal from abnormal values of skeletal muscle mass.

Several approaches can be adopted to identify critical cut-points. A paradigmatic example potentially lending support to the approach previously adopted to identify osteoporosis on the basis of bone mineral density. In fact, approaches that have been developed for bone and osteoporosis may serve well for skeletal muscle and sarcopenia. The clinical definition of a specific condition (which will consequently lead to the indication for treatment) might be based on:

1) A parallel clinical diagnosis. For osteoporosis, diagnosis can be obtained by evaluating the presence of vertebral fractures or deformities at the X-ray examination. Vertebral fractures indicate decreased bone strength, regardless of bone mineral density. It is well-established that patients with vertebral fractures present an increased risk of new events, and therefore require treatment. This approach is legitimate and may well work, but may find some limitations when applied in primary prevention.

2) A biological assessment. Given its well-established association with fracture risk, bone mineral density may represent the key parameter on which to rely to determine the presence or absence of osteoporosis. However, bone mineral density (like any other biological marker) exists as a continuous variable, does not present a clear threshold, and is parallel to gradients of risk. Although necessary to provide clinical relevance to biological markers, any categorization therefore require treatment. This approach is legitimate and may well work, but may find some limitations when applied in primary prevention.

Several approaches can be adopted to identify critical cut-points. A paradigmatic example potentially lending support to the approach previously adopted to identify osteoporosis on the basis of bone mineral density. In fact, approaches that have been developed for bone and osteoporosis may serve well for skeletal muscle and sarcopenia. The clinical definition of a specific condition (which will consequently lead to the indication for treatment) might be based on:

1) A parallel clinical diagnosis. For osteoporosis, diagnosis can be obtained by evaluating the presence of vertebral fractures or deformities at the X-ray examination. Vertebral fractures indicate decreased bone strength, regardless of bone mineral density. It is well-established that patients with vertebral fractures present an increased risk of new events, and therefore require treatment. This approach is legitimate and may well work, but may find some limitations when applied in primary prevention.

2) A biological assessment. Given its well-established association with fracture risk, bone mineral density may represent the key parameter on which to rely to determine the presence or absence of osteoporosis. However, bone mineral density (like any other biological marker) exists as a continuous variable, does not present a clear threshold, and is parallel to gradients of risk. Although necessary to provide clinical relevance to biological markers, any categorization therefore require treatment. This approach is legitimate and may well work, but may find some limitations when applied in primary prevention.
3) The risk of adverse clinical outcomes. The indication to treatment of a specific condition (e.g., osteoporosis) might be based on the evaluation of risk of events (i.e., fractures) resulting from the assessment of multiple factors (which may even not include bone mineral density) (49). This approach will not be exclusively based on the single evaluation of a (potentially inaccurate and/or arguable) biomarker, but on a more comprehensive screening and on cost-effectiveness analyses (e.g., treat if the 10-year risk is exceeding a critical threshold). With this rationale, the FRAX (50) and QFractureScores(51) algorithms were recently developed to guide osteoporosis treatment.

In summary, the presence of sarcopenia might be determined by 1) relying on a clinical diagnosis closely related to skeletal muscle decline (e.g., mobility disability) after exclusion of secondary causes, 2) a representative scientific committee identifying a critical threshold for a biological parameter directly representative of skeletal muscle health, and/or 3) developing a risk index to guide treatment.

**Biological markers of sarcopenia**

Given the syndromic nature of sarcopenia, intervention strategies aimed at preventing/treating its process might need to target multiple risk factors. In this context, several biological markers have been shown to be associated with skeletal muscle mass, strength and function, thus representing potential markers for the effect of the studied interventions. Such a list is quite long, and each biomarker identifies a specific mechanism contributing the age-related skeletal muscle decline, although they are not specific to muscle and many are likely to turn out to be only weakly associated with clinically relevant outcomes. The most common markers are inflammatory biomarkers [e.g., C-reactive protein (52, 53), interleukin-6 (52-54), and tumor necrosis factor-α (52, 54)], clinical parameters [e.g., hemoglobin (55, 56), serum albumin (57, 58), urinary creatinine (59)], hormones [e.g., dehydroepiandrosterone sulfate (60), testosterone (61), insulin-like growth factor-1 (62), and vitamin D (63-65)], products of oxidative damage [e.g., advanced glycation end-products (66), protein carbonyls (67, 68), and oxidized low-density lipoproteins (69)], or antioxidants [e.g., carotenoids (70, 71), and α-tocopherol (70)].

Other promising biomarkers have been identified in the last years and may represent useful parameters to more directly explore sarcopenia because they are closely related to skeletal muscle changes. For example, plasma concentrations of procollagen type III N-terminal peptide (P3NP) represent an interesting marker of skeletal muscle remodeling (72, 73). P3NP is a fragment released by the cleavage of procollagen type III to generate collagen III (a protein produced in soft connective tissues, skin, and muscle). Preliminary studies have also suggested an interesting role played by biomarkers specifically linked to the neuromuscular junction in evaluating skeletal muscle modifications (74, 75).

**Clinical outcome measures of sarcopenia**

Ultimately, the goal of clinical trials for sarcopenia treatments will require the evaluation of clinical benefit. In fact, clinical measures can also be considered as biomarkers as they reflect the impact of the pathological process of sarcopenia on the patient's health. The assessment of measures of muscle strength (e.g., hand grip), muscle power (e.g., leg extension power), and physical performance [e.g., Short Physical Performance Battery (4) and gait speed tests] comprise important indices of the individual's physical function. In addition, functional outcome measures will need to be developed in order to help understand the impact of any treatment-related quantitative gains in performance on the person's daily life.

**Recommendations**

**Adoption of comprehensive operative definitions**

The lack of a unique operative definition of sarcopenia and the numerous methodological issues could potentially hinder efforts to study sarcopenia and to develop effective treatments. Such difficulties should not hamper the process of exploring this syndrome which severely affects the health status of millions of older persons. The current ambiguities can be easily overcome by adopting flexible and comprehensive approaches in the design of studies, for example by avoiding reliance on a single parameter or technique to evaluate age-related skeletal muscle decline. The adoption of a variety of assessment approaches in combination is agreeable. Although this might lead to the risk of conflicting results (and increase the need of resources), it will serve to 1) capture different domains of the sarcopenia syndrome, 2) provide useful insights about the pathophysiological process underlying this phenomenon, and 3) facilitate the development and use of the findings in future and more definitive studies. In this context, it is noteworthy the lack of studies simultaneously testing different techniques measuring skeletal muscle (e.g., MRI, CT, DXA, etc) in relationship with clinically meaningful outcomes. Such studies might greatly help in the standardization of instruments and in the adoption of an univocal direction in the study of sarcopenia.

**MRI and CT scan to be equally considered as “gold standard” imaging techniques**

It is now clear that to be adequately assessed, the sarcopenia phenomenon cannot merely rely on the evaluation of the contractile part of skeletal muscle. The close relationship between lean mass and adipose tissue in determining age-related decline of skeletal muscle is evident (38, 76, 77).
Therefore, techniques allowing the simultaneous evaluation of fat and muscle should be preferred. DXA, CT and MRI are the most important assessment instruments. CT and MRI should be considered the “gold standard” techniques. The balance of pros and cons for both CT and MRI does not allow a clear indication on which of the two should be preferred. Resources, instrument availability, and need of details will represent the factors guiding the investigator’s preference for one over the other. On the other hand, DXA should not be discarded, and still represents the instrument more likely to promote the “clinical relevance” of sarcopenia. For its characteristics, DXA may be an extremely interesting methodology to be used for preliminary screening. Moreover, its use in combination with either CT or MRI will help drive the research in the field towards more clinical aspects. While imaging and other biomarkers will be valuable tools for initial proof of concept studies, assessment tools for evaluating the effect of treatments on outcomes reflecting clinical benefit will be required to support eventual pivotal studies.

**Adequate length of study**

To evaluate the efficacy of a specific intervention on sarcopenia, it is necessary that the follow-up will be sufficiently long to allow the hypothesized modifications of biomarkers. Surely, not all biomarkers will be similarly influenced by the intervention. Such variations will depend on multiple factors, including the population characteristics, the type and strength of the tested intervention, and the sensibility of the biomarker to changes. However, six months have been generally indicated as the minimum timeframe to expect changes in imaging parameters.

**Sarcopenia is a “work in progress”**

The study of sarcopenia is still in its infancy, but we have clearly acknowledged the great potential benefits arising from the understanding and treatment of this condition at both person and population levels. Taking together the uncertainties of exploring a novel field with the exponential acceleration of scientific progress, it is currently difficult to provide long-lasting statements, recommendations, and guidelines. It is likely that what seems reasonable today will be confounded by several studies in the near future. For this reason, extreme caution is needed to avoid jeopardizing the future development of research in the field. It is important to consider the study of sarcopenia as a “work in progress”, always amenable to changes and redirections. After all, the first Phase II trials in this syndrome are just starting, and this is the appropriate time to raise doubts and pose questions. With time, a stronger foundation for sarcopenia research will be developed that will ultimately lead to larger scale and more definitive studies. In this context, it is critical that an ongoing dialogue be initiated and sustained amongst investigators with an interest in age-dependent decline of muscle.

**Acknowledgements:** Dr. Fielding’s contribution is based upon work supported by the US Department of Agriculture, under agreement No. 58-1950-7-707.

**Members of the International Working Group on Sarcopenia:**

Gabor Abellan Van Kan, France; Sandrine Andrieu, France; Stefan D. Anker, Germany; Patricia Anthony, Switzerland; Christian Ashrand, Germany; Mylène Aubertin-Leheudre, Canada; Sebastien Barbart-Artigas, Canada; Olivier Benichou, France; Cécile Bonhomme, France; Pascale Borensztein, France; Denis Breuilé, Switzerland; Sergio Castro Henríquez, Chile; Jesse M. Cedarbaum, USA; Matteo Cesari, France; Patricia Chatelain, France; Wm. Cameron Chumlea, USA; Richard V. Clark, USA; Capucine De Meynard, France; William J. Evans, USA; Gary Fanjiang, USA; Luigi Ferrucci, USA; Roger A. Fielding, USA; Philippe Garnier, France; Sophie Gillette-Guyonnet, France; Bret Goodpaster, USA; Marie-Françoise Gros, France; Luis Miguel F. Gutierrez Robledo, Mexico; Marc Hellerstein, USA; Kelly Krohn, USA; Maria Isaac, United Kingdom; Didier Laurent, Switzerland; Menghua Luo, USA; Hélène Matheix-Fortunet, France; Inge Mohede, The Netherlands; John E. Morley, USA; Christine M’Rini, France; Ramon Navarro, France; Bruno Oesch, Switzerland; Reinhard Ommerborn, Germany; Marco Pahor, USA; Donald Rejeski, France; Yves Rolland, France; Daniel Rooks, USA; Ronnen Roubenoff, USA; Fariba Roughhead, Switzerland; Seward Rutkove, USA; Cornel C. Sieber, Germany; Michele Storrs-Malibat, France; Stephanie Studenski, USA; Yannis Tsouderos, France; Bruno Vellas, France; Sjors Verlaan, The Netherlands; Stephan Von Heuchling, Germany; J. Willem Vrijbloed, Switzerland; Sander Wijers, The Netherlands; Mauro Zamboni, Italy.

**Conflicts of interest:** MC has received consultancy fees from Sanofi-Aventis and Pfizer; RAF is consultant with Merck, Eli Lilly, Cytokinetics, DMI, Kraft Foods, and Unilever; MH is stockholder, chairman of scientific advisory board and consultant for KineMed, Inc.; SA is consultant with Brahms, Vifor, Professional Dietetics, Psodxus, Takeda, receives research support from Vifor, BG Medicine, and has received fees for speaking at meetings from Brahms, Vifor; SR has equity in and receives consulting income from Convergence Medical Devices, Inc; WV is employee and shareholder of Neurontin AG; YR receives support from Lectalis, Lundbeck, Lilly, Nutricia, Servier, Cheisi, Ipsen, Novartis; JMC is employee and shareholder of Cytokinetics, Inc; MZ has received a fee from Abbot for a conference; DL and RR are employed by Novartis; WJE is employed by GlaxoSmithKline; JEM is consultant and stakeholder of Mattern Pharmaceuticals and consultant for Sanofi-Aventis; BV is consultant and member of Advisory Board with Novartis, Servier, Nestlé. MP, BG, GAVK, MI, CMR, MAL, CCS have no conflict of interest to declare.

**Disclaimer:** Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the Authors and do not necessarily reflect the position of the supporting organizations or agencies.
References


BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS


